The G8 Pharmaceuticals industry guide provides top-line qualitative and quantitative summary information including: market share, market size (value , and forecast to 2019). The guide also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Features and benefits
* Save time carrying out entry-level research by identifying the size, growth, and leading players in the G8 pharmaceuticals market * Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 pharmaceuticals market * Leading company profiles reveal details of key pharmaceuticals market players’ G8 operations and financial performance * Add weight to presentations and pitches by understanding the future growth prospects of the G8 pharmaceuticals market with five year forecasts * Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country
The G8 countries contributed $554.1 billion in 2014 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 3.3% between 2010 and 2014. The G8 countries are expected to reach a value of $684.8 billion in 2019, with a CAGR of 4.3% over the 2014-19 period. Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $303.9 billion in 2014. This was followed by Japan and Germany, with a value of $85.5 and $37.1 billion, respectively. The US is expected to lead the pharmaceuticals industry in the G8 nations with a value of $390.7 billion in 2016, followed by Japan and Germany with expected values of $102.2 and $44.8 billion, respectively.
Your key questions answered
* What was the size of the G8 pharmaceuticals market by value in 2014? * What will be the size of the G8 pharmaceuticals market in 2019? * What factors are affecting the strength of competition in the G8 pharmaceuticals market? * How has the market performed over the last five years? * Who are the top competitors in the G8 pharmaceuticals market?
Our reports have been used by over 10K customers, including:
Aortic Aneurysm Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Aortic Aneurysm Global Clinical Trials Review, H2, 2018" provides an overview of Aortic Aneurysm clinical trials scenario.This report provides top line data relating to the clinical trials on Aortic...
Optic Nerve Disorders Drug Development Pipeline Review, 2018 Summary Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 10 products in development for this indication. Glaucoma is a disease of...
Left Ventricular Dysfunction - Pipeline Review, H1 2019 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Left Ventricular Dysfunction - Pipeline Review, H1 2019, provides an overview of the Left Ventricular Dysfunction (Cardiovascular) pipeline landscape. Left...